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Herein we will review the role of glycans in the immune system. Speciﬁc topics covered include: the
glycosylation sites of IgE, IgM, IgD, IgE, IgA, and IgG; how glycans can encode “self” identity
by functioning as either danger associated molecular patterns (DAMPs) or self-associated molecular
patterns (SAMPs); the role of glycans as markers of protein integrity and age; how the glycocalyx can
dictate the migration pattern of immune cells; and how the combination of Fc N-glycans and Ig isotype
dictate the effector function of immunoglobulins. We speculate that the latter may be responsible for the
well-documented association between alterations of the serum glycome and autoimmunity. Due to
technological limitations, the extent of these autoimmune-associated glycan alterations and their role in
disease pathophysiology has not been fully elucidated. Thus, we also review the current technologies
available for glycan analysis, placing an emphasis on Multiple Reaction Monitoring (MRM), a rapid
high-throughput technology that has great potential for glycan biomarker research. Finally, we put forth
The Altered Glycan Theory of Autoimmunity, which states that each autoimmune disease will have a unique
glycan signature characterized by the site-speciﬁc relative abundances of individual glycan structures on
immune cells and extracellular proteins, especially the site-speciﬁc glycosylation patterns of the different
immunoglobulin(Ig) classes and subclasses.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction and The Altered Glycan Theory of
Autoimmunity
Since the discovery of altered IgG glycosylation in patients with
rheumatoid arthritis [1], there has been mounting evidence favor-
ing the role of glycans in the pathophysiology of autoimmunity. For
example, it is nowwell established that the type of glycanpresent at
residue Asn-180 of IgG1 helps dictate the effector function of the
antibody, with some glycans being pro-inﬂammatory while others
possessing anti-inﬂammatory properties [2,3]. As is the case for the
Asn-180 glycan, the antibody isotype also has a strong inﬂuence
over its functionality [4]. In fact, some autoimmune diseases are
strongly linked to a particular Ig class or subclass. Prototypic
examples include the IgG4-mediated diseases, pemphigus foliaceusx: þ1 (916) 442 5702.
rakis).
r Ltd. This is an open access articleand autoimmune pancreatitis [5,6]. Thus, in antibody-mediated
autoimmunity, antigen speciﬁcity will determine the site of attack
whereas the glycan/Ig isotype combinationwill dictate the physical
nature of the attack. Based on these and other fundamentals
described herein we put forth The Altered Glycan Theory of Autoim-
munity, which states that each autoimmune disease will have a
unique glycan signature characterized by the site-speciﬁc relative
abundances of individual glycan structures present on immune cells
and extracellular proteins, especially the site-speciﬁc glycosylation
patterns of the different Ig classes and subclasses. This review will
also discuss the role of glycans in the immune system and how
novel Mass Spectrometry (MS) technologies, speciﬁcally Multiple
Reaction Monitoring (MRM), can be used to rapidly identify the
glycan signatures of the different autoimmune diseases. [For
clariﬁcation Asn-180 of IgG1 corresponds to Asn-176 of IgG2, Asn-
227 of IgG3, and Asn-177 of IgG4. Using the International
Immunogenetics Information System (IMGT) numbering protocolunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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number, CH2-84.4, regardless of IgG subclass. An addition point of
potential confusion is that Asn-180 is also sometimes referred to as
Asn-297, if one attempts to sequentially number all amino acids
within the IgG molecule. Thus, for simplicity, this review will refer
to the conserved IgG glycosylation site as CH2-84.4].2. A brief overview of antibody structure
Humans have ﬁve distinct classes of immunoglobulins (Igs): IgG,
IgM, IgA, IgE, and IgD (Fig.1). IgA and IgG can be further divided into
two (IgA1-2) and four (IgG1-4) subclasses, respectively. All Igs
are comprised of two 50e77 kDa class-speciﬁc heavy chains (g, m, a,
ε and d) that are joined together by one or more disulﬁde bonds
(Fig. 1). Each heavy chain is also joined by a disulﬁde bond to a
25 kDa light chain, which can be one of two different isoforms
(k and l). For IgM and IgA, disulﬁde bonds can further connect
individual Igs (an their associated J chains) to form pentamer and
dimer structures, respectively (Fig. 1). The antigen-recognition
region of an Ig is referred to as its Fab fragment. In contrast, theFig. 1. Immunoglobulin Isotypes and their sites of glycosylation. Depicted here are the an
272, 279, and 439 (UNIPROT), or CH1-45, CH2-120, CH3-81, CH3-84.4, and CHS-7 (IMGT
[(N-glycans at Asn-47, 92, 131, 205, 327 (UNIPROT) or CH1-45.2, CH1-114, CH2-20, CH2-120
Asn-177 (IgG4), and Asn-322 (IgG3) (UNIPROT) or CH2-84.4 (IgG1-4) and CH3-79 (IgG3) (IM
116 (IMGT)], and IgE [(N-glycans at Asn-21, 49, 99, 146, 252, 264, 275 (UNIPROT) or CH1-1
noglobulin is comprised of two heavy chains (blue) and two light chains (purple) that are l
region that link the Igs' antigen-binding Fab region to their Fc receptor-binding region. O-gly
The depicted glycans are important for the structural integrity of the antibodies and their eff
reader is referred to the web version of this article.)Fc fragment is comprised of the heavy chain region that interacts
with the Fc receptors on immune cells. In the IgA, IgD, and IgG
isoforms, a ﬂexible linker, which can be decorated with glycans,
separates the Fab and Fc regions. IgM and IgE lack this hinge region
and are thus more rigid in structure. IgG1,2,4 have a single
conserved N glycosylation site at residue CH2-84.4 where large
(2 KDa) ﬂexible glycans attach. The other Igs are more heavily
glycosylated (Fig. 1). As will be discussed in later sections, these
glycan modiﬁcations are critical for the appropriate function of all
Igs.3. A vast amount of information is stored in a cell's glycocalyx
Along with nucleic acids, proteins, and lipids, glycans are one of
the four fundamental classes of molecules that make up all living
systems [7]. However, in comparison to the advances made in the
ﬁelds of genomics and proteomics, glycoscience remains relatively
understudied, a disturbing fact given that glycans play a major
role in the etiology of all human diseases [8]. Traditionally, the in-
formation stream of a cell is viewed as starting in the genometibody structures including their sites of glycosylation: IgM [(N-glycans at Asn-46, 209,
)]; IgA1 [(N-glycans at Asn-144 and 352 (UNIPROT) or CH2-20, CHS-7 (IMGT)]; IgA2
and CHS-7 (IMGT)]; IgG [(N-glycans at Asn-180 (IgG1), Asn-176 (IgG2), Asn-227 (IgG3),
GT)]; IgD [(N-glycans at Asn-225, 316, and 367 (UNIPROT) or CH2-84.4, CH3-45.4, CH3-
5.2, CH1-45.2, CH1-118, CH2-38, CH3-38, CH3-77, and CH3-84.4 (IMGT)]. Each immu-
inked together by disulﬁde bonds (black lines). IgA, IgD, and IgG have a ﬂexible hinge
cosylation sites are depicted in yellow and N-glycosylation sites are depicted in brown.
ector function [2]. (For interpretation of the references to color in this ﬁgure legend, the
E. Maverakis et al. / Journal of Autoimmunity 57 (2015) 1e13 3and ending with a set of expressed proteins, representing the
cell's phenotype. Once synthesized, proteins can interact with other
proteins to form networks. However in order for a protein to
function appropriately, it often requires a post-translational modi-
ﬁcation and glycans are one of themost commonly addedmodiﬁers
(Fig. 2). Thus, they can be considered the ﬁnal step in the cell's
information stream. Following this logic, it has been suggested that
the proteome predicts the phenotype but the glycome actually is the
phenotype [8]. Supporting this view is the fact that glycans can
function as protein “on and off” switches or as “analog regulators” to
ﬁne-tune protein function [8]. But how is information storedwithin
the glycome?
First, let us establish that glycan structures are sufﬁciently
complex for information storage. A cell is able to synthesize
thousands of unique glycan structures by linking together a ﬁnite
set of sugar monomers [9] (Fig. 2). Unlike DNA, RNA and proteins,
glycan synthesis is not a template driven linear process. The spe-
ciﬁc glycans found at a particular site along a protein can be very
heterogeneous, reﬂecting the cell's narration including its history
of expressed genes and its environmental encounters. Ultimately,
each glycan structure will contain some information about the
cell. This information is different from, but complementary to, the
genetic information stored in the cell's nucleus [8]. When one
considers the massive 3-dimensional structural diversity ofFig. 2. A limited number of sugar monomers can create thousands of complex glycans. P
folding, steric protection from proteolytic degradation, and regulation of proteineprotein
The glycans are attached to proteins via “N” or “O” linkages, with N-glycosylations being mor
attached to amino acids serine (Ser) or threonine (Thr). Depicted here is the process of N-
N-glycans are attached to proteins at speciﬁc motifs; Asparagine-X-Serine or Asparagine-
N-glycosylation, monosaccharides (often donated by UDP or GDP-sugars) are sequentially
consecutively to Dol in the cytosol. This is followed by the addition of several mannose (Man
ﬂipped into the ER-lumen. Then, four additional Man residues are added. This is followed
Glc3Man9GlcNAc2-PP-dolichol precursor glycan, which is then transferred to an Asn residue
precursor glycan to potentially generate over 10 thousand unique structures, which can b
Complex). Although not depicted here, N-glycans containing a “bisecting” N-acetylglucosamglycans combined with the variation in their attachment sites, the
potential for information to be stored within the glycocalyx par-
allels that of the genome. But in contrast to a cell's genetic infor-
mation, we are just beginning to understand the information
stored within the glycome. In this regard, glycoscience is similar to
where the ﬁeld of genetics was during the initial stages of the
genome project [8].
If the glycan code has yet to be deciphered, and for the most part
the exact structures and attachment sites of human glycans
are largely unknown, how can we be certain that information is
actually storedwithin the glycome? The answer is simple. Although
science has yet to develop the tools needed to understand the
glycome, nature has already done so. Lectins are carbohydrate-
binding proteins that are used by cells and microbial pathogens
to interpret the glycome [10]. They have complex speciﬁcities that
not only incorporate select sugar monomers such as galactose,
mannose, and fucose but also carbohydrate branching, spacing, and
multivalency. To highlight how lectins can harvest the information
stored within the glycome, we provide the following three
examples.
Example 1: Self Identity is displayed by the glycocalyx. The role
that glycans play in the pathophysiology of disease is not sur-
prising considering every cell in the human body is decoratedost-translational glycan modiﬁcations are generally thought to be important for protein
interactions. It is estimated that up to 70% of mammalian proteins are glycosylated.
e common. N-glycans are attached to asparagine (Asn) residues, whereas O-glycans are
glycosylation, which begins in the endoplasmic reticulum (ER) and ends in the Golgi.
X-threonine, where X can be any amino acid except proline. During the process of
added to the glycan structure. Initially, two N-Acetylglucosamine residues are added
) residues. After formation of the intermediate (Man5HexNAc2-PP-Dol), the complex is
by the addition of 3 glucose (Glc) residues, donated by Glc-P-dolichol, to form the
on a newly synthesized protein. Glycosidases and glycosyltransferases then modify the
e separated into three very broad structural categories (High Mannose, Hybrid, and
ine residue can also be generated.
Fig. 3. Asialoglycoprotein receptors. Sialylated serum proteins and cells are not
recognized by asialoglycoprotein receptors in the liver and are thus protected from
uptake and degradation. However, as an initially sialylated molecule ages it progres-
sively loses its sialic acid moieties making it a target for asialoglycoprotein receptors. In
the liver these receptors identify desialylated proteins, targeting them for uptake and
degradation.
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mune system is tasked with surveying the body for “danger”,
the glycocalyx will be routinely engaged when an immune cell
contacts another cell or for that matter any component of its
environment [11]. In such interactions, glycans help dictate the
behavior of immune cells. Although the exact molecular struc-
tures and attachment sites of the glycan components of the
human immune system are poorly characterized, it is clear that
they play a major role in all of the fundamental functions of the
immune system, the most basic of which is “self/non-self”
discrimination, as described below.
In order for the immune system to respond to an invading
pathogen or other imminent threat, it needs to ﬁrst identify the
threat as “non-self”. Since the late 1990's several seminal discov-
eries have demonstrated how the immune system can recognize
and respond to foreign patterns [12e14]. As it turns out many of the
“pathogen-associated molecular patterns” (PAMPs) and “danger
associated molecular patterns” (DAMPs) are glycoconjugates, and
their immune receptors are lectins. Examples include the soluble
mannose-binding lectins (MBLs), which recognize foreign glycan
patterns present on microbes and injured host cells. MBLs form
complexeswithMBL-associated serine proteases (MASPs), which in
turn activate complement to destroy the microbial pathogen or
potentially dangerous host cell [15] (Later in this review we will
provide a speciﬁc example of how glycan alterations in the setting
of autoimmunity can result in MBL-mediated tissue injury).
Many other pattern recognition receptors, including most of the
a-defensins, have similar carbohydrate-binding properties [16].
Not as well understood, but of equal importance, is how lectins
within the immune system recognize “self-associated molecular
patterns” (SAMPs) to prevent robust responses to non-pathogenic
stimuli [17]. Sialic acid-containing glycans likely function as
SAMPs and Siglecs (e.g., CD33), Factor H, and CD24 have all been
identiﬁed as potential SAMP-recognizing receptors that can repress
immune responses [18]. There are at least 16 sialic acid-binding
Ig-like lectins (Siglecs) expressed by different leukocyte pop-
ulations [19]. Some of these interpret non-pathogen glycans as
“self” and deliver inhibitory signals to immune cells to prevent
them from becoming over stimulated. Certain C-type lectin re-
ceptors (CLRs) on the surface of dendritic cells likely also function
as SAMP receptors. CLRs help instruct dendritic cells as to when it is
appropriate to induce immune tolerance rather than lymphocyte
activation [20,21]. Examples of CLRs expressed by immature
monocyte derived dendritic cells include CD206, DEC-205,
DC-SIGN, BCDA-2, Dectin-1, DCIR, DCAL-1, C-LEC, and DC-ASGPR.
As a testament to how important the above interactions are,
“self” glycans and their receptors are rapidly evolving to foil at-
tempts by pathogenic microbes to mimic SAMPs in an effort to
avoid immune recognition [22,23]. Similarly, “self” glycans also
evolve to hide from viruses and other microbes that use host
glycans as microbial-binding sites to establish infections [17].
With respect to autoimmunity, a deﬁciency in SAMP-mediated
signaling might predispose an individual to develop an autor-
eactive immune response. As described later, depending on their
structure, the glycans present on IgG can function as either DAMPs
or SAMPs, with the ability to potentiate or suppress an autoreactive
immune response, respectively. Careful characterization of these
glycans will likely yield new biomarkers of autoimmunity.
Ultimately the identiﬁcation of novel serum SAMPs will enable
investigators to design 'glycomimetics' as immunomodulatory
drugs for the treatment of autoimmune diseases. .
Example 2: Information on “Age” is stored within the glycocalyx. A
classic example of this is the clearance of old erythrocytes andglycoproteins from the blood [24]. As an erythrocyte ages, it
becomes progressively de-sialylated, which in turn increases the
density of exposed galactose moieties on its surface. This allows
for asialoglycoprotein receptors (ASGP-R) in the liver to identify
the old erythrocytes and signal for their destruction [25].
Within the immune system sialic acid moieties sometimes
identify the maturation state on immune cells. For example, the
density of sialic acid on the T cell surface changes over time. Naïve T
cells express CD45 that is modiﬁed with a2,6-linked sialic acid. The
amount of a2,6-linked sialic acid is signiﬁcantly reduced following
T cell activation. This decrease in a2,6-linked sialic acid renders the
activated T cells more susceptible to galectin-1 mediated apoptosis
[26]. Interestingly, CD4þ Th2 cells are resistant to galectin-1
mediated apoptosis because their expression of a2,6-linked sialic
acid is not decreased [27]. The exact structure and location of the
sialic acid containing glycans have not been well established but
since thesemoieties are differentially expressed on activated versus
naïve T cells, theymight contribute to a unique autoimmune glycan
signature.
As is the case with old erythrocytes, the liver also uses de-
sialylation to purge non-functional proteins from the circulation
(Fig. 3). Clearance of IgA is mediated at least in part by ASGP-Rs,
which recognizes galactose-terminating IgA N-glycans [28,29].
Differing from IgG, IgA1 and IgA2 have two conserved N-liked
glycosylation sites, one on the CH2 domain and the other on their
CHS tailpiece [2]. Apart from these, IgA2 has three additional
N-linked glycosylation sites and IgA1 has several additional
O-glycosylation sites. As a result of their increased accessibility to
glycosyltransferases, IgA glycans are more likely to be sialylated,
which allows IgA clearance to be regulated byASGP-Rs. In the setting
of IgA-mediated nephropathy, alterations in IgA1 glycans have been
well documented [30]. Decreased sialylation and galactosylation
results in altered IgA1 aggregation and impaired ASGP-R-mediated
clearance. Together these contribute to the onset of nephropathy
[31]. Theoretically, these isotype-speciﬁc glycan alterations are part
of a unique glycan signature indicative of IgA-mediated autoim-
munity. (Of note, the liver does not target de-sialylated IgG for
clearance and thus the CH2-84.4-attached glycans do not regulate
IgG half-life. This task seems to be carried out by the neonatal Fc
receptor, which keeps IgG levels constant [32,33]).
Fig.
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for a leukocyte to extravasate into a tissue, it must ﬁrst slow
down and roll along the endothelial surface. Leukocyte rolling is
initiated by selectins, which are highly regulated glycan-binding
glycoproteins. Selectins are exquisitely speciﬁc at binding to
certain glycan structures. For example, the high endothelial
venules of the secondary lymphoid tissues express the ligand for
L-selectin, the glycosylation-dependent cell adhesion molecule-
1 (GlyCAM-1). Since L-selectin (also known as CD62L) is
expressed by naïve and central memory T cells, binding of
L-selectin to GlyCAM-1 homes these T cells to the lymph nodes.
In contrast, effector memory T cells lack L-selectin and thus stay
in the periphery [34]. In the above example, the lack of a gly-
coconjugate prevents the effector memory T cells from homing
to the lymph nodes. However, sometimes the difference is even
more subtle. For example, skin-inﬁltrating T cells express the
cutaneous lymphocyte-associated antigen (CLA), which con-
tains a carbohydrate epitope recognized by the monoclonal
antibody, HECA-452. CLA mediates lymphocyte migration to the
skin through its interaction with E-selectin. Remarkably, it was
discovered that CLA is actually an inducible carbohydrate
modiﬁcation of P-selectin glycoprotein ligand-1 (PSGL-1), a
glycoprotein expressed by all human T cells [35]. This is an
excellent example of a glycan functioning as an “on-off” switch.
In the case of CLA, the CLA-speciﬁc glycans “turn on” PSGL-1's
skin-homing function (Fig. 4). Other lectins such as DC-SIGN
might also participate as rolling receptors. Thus, the process is
regulated by a repertoire of glycans present on both the effector
and target cells (e.g. lymphocytes and endothelial cells,
respectively) [36]. Given that autoimmunity is often organ-
speciﬁc it is likely that the autoreactive cells will have unique
tissue-homing glycan signatures, which could potentially serve
as novel glycan biomarkers of autoimmunity. With a better
understanding of the glycan signatures that home
lymphocytes to different anatomical sites, exquisitely speciﬁc4. Cutaneous Leukocyte Antigen (CLA) is a glycovariant of P-selectin glycoprotein ligand
egulated on endothelial cells in the setting of inﬂammation. PSGL-1 binding to P-selectin help
resent on endothelial cells within the skin. C) Skin-homing T cells up-regulate the glycosyla
eties on PSGL-1, bestowing it with the capacity to bind to E-selectin. The sialyl-Lewis X-deco
L-1 in that it occurs as a monomer.therapeutics can be developed to inhibit inﬂammation in a
tissue-speciﬁc manner.4. The impact of Ig isotype on immunoglobulin effector
function
Although an immunoglobulin's Fab region dictates its antigen-
speciﬁcity (i.e. the site of attack for autoreactive antibodies),
effector function is determined by the Fc region [4]. For example,
FcR-bearing innate immune cells can initiate pro-inﬂammatory or
cytotoxic pathways following engagement of their FcRs with
antigen-bound multimeric Ig complexes [37e39]; the particular
type of response induced by this interaction will depend on the
FcRs that are engaged. Fc receptors are a family of glycoproteins
that are comprised of an IgG-binding subunit that, depending on
the receptor, may pair with accessory g, z, or b subunits, which
are important for receptor signaling [40]. In humans there are three
classes of FcRs: FcgRI, FcgRII, and FcgRIII (Fig. 5). These can be
broadly categorized as either inhibitory FcRs (FcgRIIB) or activating
FcRs (FcgRI, FcgRIIA, and FcgRIIIA) [4]. With the exception of FcgRI,
which has a high afﬁnity for monomeric IgG, all other FcRs bind to
multimeric antigeneantibody complexes [4]. The afﬁnity of the FcR
for these complexes depends on the subclass of the complexed IgGs
(Fig. 5).
With respect to the different activating FcRs, the consequences
of their engagement will depend on the type of cell that expresses
them (Fig. 5), as different cell types have markedly different
effector responses. Additionally, the same FcR can be linked to
different signaling molecules when expressed by different cell
types [4]. Common effector functions initiated by activating
FcRs include: phagocytosis, antigen processing, cytokine release,
degranulation and antibody-dependent cellular cytotoxicity
(ADCC) [41,42]. However, individual activating FcRs can initiate
different cellular responses even when expressed by the same-1 (PSGL-1). A) PSGL-1, present on the surface of T cells, binds to P-selectin, which is
s initiate leukocyte rolling. B) In contrast, PSGL-1 does not bind to E-selectin, which
tion enzyme FucT-VII, which leads to an increase in the number of sialyl-Lewis X
rated E-selectin-binding glycoform of PSGL-1 is called CLA, which also differs from
Fig. 5. Fc receptors can have unique Ig speciﬁcities. FcgRI, FcgRIIA, FcgRIIIA are activating Fc receptors that differ in their afﬁnities for the individual IgG subclasses; the only
commonality being that each of them binds best to IgG1. Of the activating receptors, FcgRI is unique in that it can bind with high afﬁnity to monomeric IgG antibodies. In contrast,
FcgRIIA and FcgRIIIA are low afﬁnity Fc receptors that bind only to antigeneantibody complexes. Activating signals originating from FcReIg interactions can be initiated by
intracellular immunoreceptor tyrosine-based activation motifs (ITAMs), either within the Fc receptor or as part of the Fc receptor complex. In contrast, FcgRIIB is a low afﬁnity
inhibitory Fc receptor, which has an immunoreceptor tyrosine-based inhibition motif (ITIM) as part of its cytoplasmic domain. FcgRIIIB, found exclusively on neutrophils, is an
activating glycosylphosphatidylinositol (GPI)-linked receptor.
Table 1
Disease speciﬁc antigens and immunoglobulin subclasses.
Autoimmune disease Known antigens Ig Reference
Autoimmune Pancreatitis Unspeciﬁed IgG4 [6]
Chronic Inﬂammatory
Demyelinating
Polyradiculoneuropathy
(CIDP)
Neurofascin 155 IgG4 [101]
Hashimoto's
Thyroiditis (HT)
Thyroid Peroxidase IgG4 [102]
Thyroglobulin IgG4
Pemphigus Foliaceus Desmosome-associated
glycoprotein
IgG4 [5]
Pemphigus Vulgaris Desmoglein 3 IgG1, IgG4 [103]
IgA Nephropathy Unspeciﬁed IgA1/IgA [104]
Thyroid Eye
Disease (TED)
Calcium binding protein
(calsequestrin)
IgG1, IgG3 [105]
Grave's Disease Thyroid Stimulating
Hormone Receptor
IgG3/IgG [106]
Primary Biliary
Cirrhosis (PBC)
Antimitochondrial
antibodies (AMAs)
IgM [107,108]
Antinuclear
antibodies (ANA)
IgG3
Rim-like/membrane
(RL/M)
IgG1
Multiple nuclear
dot (MND)
IgG3
E. Maverakis et al. / Journal of Autoimmunity 57 (2015) 1e136cell. For example, human neutrophils express two activating FcRs,
FcgRIIA and FcgRIIIB. When engaged, FcgRIIA increases L-selectin
expression [43] and promotes phagocytosis [44]. In contrast,
engagement of FcgRIIIB results in robust phosphorylation of
ERK and the transcription factor ELK-1 and increased b1 integrin
activation [45,46].
Signals originating from the activating FcRs are balanced by
those from the inhibitory FcR, FcgRIIB, which helps to regulate the
antigen-IgG-induced activation threshold of FcR-expressing
cells, maintain peripheral tolerance, and ultimately terminate IgG
mediated inﬂammatory effector responses. FcgRIIB is expressed by
a variety of innate immune effector cells (except for NK cells) but
unlike other FcRs, FcgRIIB is unique in that it is also expressed by B
cells. The expression pattern of the different FcRs is regulated by a
variety of environmental factors including the presence of: LPS,
interleukins, TNF, complement proteins, and TGF-b [38]. Aberrant
increases of a particular FcR will result in an imbalanced immune
response that can lead to either a pro- or anti-inﬂammatory state
depending on the integration of FcR-originating activating and
inhibitory signals. For example, without FcgRIIB, mice develop
autoimmunity in a B cell-autonomous manner, demonstrating
FcgRIIB's direct role in maintaining self-tolerance [47]. Clearly,
maintaining an appropriate balance between activating and inhib-
itory FcRs can help prevent the development of autoimmunity.
IgGs of different subclasses preferentially interact with different
FcRs. It is therefore not surprising that several antibody-mediated
autoimmune diseases have been associated with a particular Ig
isotype (Table 1). IgG4-mediated diseases include pemphigus
vulgaris and autoimmune pancreatitis. In such cases the patho-
physiology of the autoimmune disease is likely linked either to the
particular Fc-binding proﬁle of the autoreactive Igs, or to some
other immunologically relevant lectin receptor that can interact
with the Igs' Fc glycan(s) (Fig. 1). As described later, detection of
biologically relevant perturbations of serum IgG subclass concen-
trations can be problematic given the large variation in normal IgG
concentrations. In the future, the relationship between antibody-
mediated autoimmunity and Ig isotype will become increasingly
apparent as investigators focus more on the relative abundance of
the different isotypes rather than their absolute concentrations. By
determining the relative abundance of the different Ig class and
subclasses and integrating this with the site-speciﬁc glycosylationproﬁles we predict that disease-speciﬁc glycan signatures will
emerge for most autoimmune diseases.4.1. Serum glycopeptides as biomarkers of autoimmunity?
With a glycoprotein concentration of 40 g/L, serum is an
excellent source of glycans to search for novel biomarkers of hu-
man disease. Unlike RNA and protein, there is no template for
glycan synthesis. Glycosylation is a process inﬂuenced by a variety
of factors including: the type of cell and its activation state;
environmental factors, such as the presence of available metabo-
lites; the age of the cell, as glycan moieties can be lost over time;
and inﬂammatory mediators, such as cytokines and chemokines.
All of these factors may be altered in the setting of autoimmunity.
For example, some autoimmune diseases have a predominant
Table 2
Variances in antibody glycan composition.
Glycan Modiﬁcation Reference
Rheumatoid Arthritis Decreased N-linked galactosylation and sialylation of IgG
Decreased N-linked galactosylation and terminal sialylation of ACPA IgG1
Increased fucosylation of ACPA-IgG1
[109,110]
IgA Nephropathy Decreased terminal O-linked galactosylation on the hinge region of IgA1 heavy chains [111e114]
Gastric Cancer Decreased galactosylation and sialylation of IgG [60]
Henoch-Schonlein Purpura Decreased galactosylation and sialylation of IgA1 [111]
HIV Decreased galactosylation, sialylation, and fucosylation in HIV-speciﬁc antibodies associated with
enhanced Fc-mediated reduction of viral replication and enhanced Fc receptor binding
[51]
Inﬂuenza and Tetanus Vaccination Increased galactosylation and sialylation of anti-vaccine IgG
Increased number of sialic acid per glucose during vaccination
Decreased IgG1 bisecting N-acetylglucosamine
[61]
Lambert-Eaton Syndrome Decreased galactosylation of IgG1 and IgG2
Increased levels of bisecting N-acetylglucosamine on IgG1 and IgG2 in patients less than 50 years old
[59]
ANCA Vasculitis Decreased galactosylation of IgG
Decreased sialylation of IgG Fab’2
[56,115]
Myasthenia Gravis Decreased galactosylation of IgG2 [59]
Ovarian Cancer Increased agalactosylated biantennary glycanson IgG heavy chains [58]
PR3-ANCA Vasculitis Decreased N-glycan 2,6-linked sialylation
Decreased galactosylation of IgG
[56,116]
Sjogren's Syndrome Decreased sialylation of IgG [117]
ACPA: anti-citrullinated protein antibodies; Ig: immunoglobulin; MPO: myeloperoxidase; PR3: anti-proteinase 3.
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expression of glycosidases, sialidases and glycosyltransferases,
which are known to impact glycan structure [48,49]. Thus, a
particular cytokine signature should theoretically be reﬂected in
the serum glycome. In some cases, cells will only synthesize a
particular glycoprotein under extreme conditions, such as within
an inﬂamed joint of a rheumatoid arthritis (RA) patient. Indeed,
during episodes of inﬂammation there are large ﬂuctuations in
serum glycoproteins, including the acute phase proteins [50].
Another factor to consider is that Ig glycosylation can be antigen-
dependent. When the glycosylation patterns of anti-HIV anti-
bodies were characterized in HIV-infected patients, researchers
discovered that anti-gp120-speciﬁc antibodies tended to be lessFig. 6. IgG Glycoforms and their inﬂammatory properties. Ig heavy chain residue CH2-84
blue, green, and yellow Y-shaped structure between the two IgG heavy chains. This glycos
linked glycan, IgG has a hydrophobic patch (not depicted). The CH2-84.4-linked glycan can
for FcgRIII and are associated with a variety of autoimmune diseases. G0 glycans termina
contrast, G2 glycans terminate with two galactose residues. CH2-84.4 glycans can also b
properties because these modiﬁcations decrease Ig afﬁnity for FcgRIII and also allow the
lated antibodies likely bind to DC-SIGN. (For interpretation of the references to color in thisialylated, and more likely to be of the G0 type when compared to
bulk anti-HIV antibodies from the same patients [51]. Since
different autoantigens are dominant in patients with various
autoimmune diseases, it is possible that this will drive unique
disease-speciﬁc glycosylation proﬁles. In summary, the resulting
serum glycome is an expression of the overall state of the indi-
vidual, making it possible for unique autoimmune signatures to be
detectable in the serum. Our speciﬁc hypothesis is that each
particular autoimmune disease will have a unique glycan proﬁle.
To identify these disease-speciﬁc signatures, we have begun to
characterize the composition and relative abundance of the
different glycan structures at speciﬁc glycosylation sites in pa-
tients with autoimmunity..4 is post-translationally modiﬁed with the addition of an N-glycan, depicted here as a
ylation site is conserved in all IgG subclasses (IgG1-4). To accommodate its CH2-84.4-
be classiﬁed broadly as being either G0, G1, or G2. G0 glycans have a higher afﬁnity
te with GlcNac residues and thus have zero galactose residues, hence their name. In
e sialylated or fucosylated, which can bestow the antibody with anti-inﬂammatory
antibody to interact with endogenous lectins on antigen presenting cells, e.g. sialy-
s ﬁgure legend, the reader is referred to the web version of this article.)
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function
The idea that glycans will be differentially expressed in the
setting of autoimmunity is supported by decades-old research.
Early insightful but technologically limited studies revealed alter-
ations of haptoglobin glycosylation in diseases such as rheumatoid
arthritis and Crohn's disease [52,53]. Other studies focused on
characterizing the IgG and IgA-linked glycans. Patients with rheu-
matoid arthritis, Lambert-Eaton myasthenic syndrome, myasthenia
gravis, Crohn's disease, juvenile arthritis, systemic lupus erythe-
matosus, IgA nephropathy and systemic vasculitis have all been
shown to have altered Ig glycosylation [1,54e64] (Table 2). The
observed changes in Ig glycosylation are of immense biological
signiﬁcance because the N-glycans present within the Fc region of
Ig help to dictate the antibody's effector function. The Fc region
CH2-84.4 glycosylation site is conserved in all IgG subclasses
(IgG1-4) and over 30 different glycans have been shown to attach
there [54]. Other classes of immunoglobulins also have N-glycans
within their Fc regions. These occur at asparagine residues 144 and
352 for IgA1; 47, 92, 131, 205 and 327 for IgA2; 21, 49, 99, 146, 252,
264, and 275 for IgE; and 46, 209, 272, 279, and 439 for IgM (Fig. 1).
However, CH2-84.4 of IgG remains the most well-characterized
glycosylation site.
To accommodate its CH2-84.4-linked glycan, IgG has a hydro-
phobic patch that utilizes more than 70 non-covalent bonds to
conﬁgure the glycan within the interstitial space between its CH2
domains. These non-covalent interactions help maintain the qua-
ternary structure and thermodynamic stability of the Ig Fc region
[65]. Thus, the CH2-84.4 glycan is critical for normal Fc function
[66]. Because of their location, CH2-84.4 glycans are difﬁcult sub-
strates for glycosyltransferases. This is of importance because the
type of glycan present at CH2-84.4 will directly impact Ig effector
function. For example, fucose containing CH2-84.4 glycans reduce
Ig afﬁnity for FcgRIIIa [67]. Speciﬁcally, fucose containing glycans at
IgG CH2-84.4 create steric hindrance and thereby prevent FcgRIIIa's
Asn-162 glycan from interacting with the Ig Fc region. Evidently,
the FcgRIIIa Asn-162 glycan is required for high avidity interactions
with the Fc region of IgG and fucose containing glycans at IgG
CH2-84.4 prevent these interactions from occurring [68].
Irrespective of their fucosylation status, IgG CH2-84.4 glycans
can be rudimentarily classiﬁed as belonging to one of three glyco-
forms: G0, G1, or G2 (Fig. 6), each having different FcR afﬁnities. G0
glycans lack galactose and terminate instead with GlcNAc moieties.
In contrast, G1 and G2 glycans contain one or two galactose resi-
dues, respectively. In patients with RA, juvenile RA, Crohn's disease,
and some forms of lupus, the glycans at CH2-84.4 were found to
often lack galactose, terminating instead with GlcNAc moieties, the
so-called G0 glycans [1,63] (Fig. 6). Increased levels of G0 glycans
also correlate with RA disease activity [69], but the cause for their
increase is not well understood. Some reports have demonstrated
an association between increases in G0 glycans and decreasedFig. 7. Multiple Reaction Monitoring (MRM) to identify glycopeptide biomarkers of au
peripheral blood is digested with trypsin to yield peptide fragments, including glycopeptides
one another utilizing Ultra High-Pressure Liquid Chromatography. The separated sample is th
of ﬂight mass spectrometry (QqQ-MS) using multiple reaction monitoring (MRM). B) MRM
peptides and glycopeptides of interest. This knowledge allows for the appropriate MRM tran
instrument optimization and knowledge of the peptide and glycopeptide retention times, b
samples with great sensitivity. Depicted here, a tryptic peptide common to the Fc region o
subclass-speciﬁc peptides (light green, purple, black, and dark green arrows) are then used fo
the individual IgG subclasses. C) Using a data set of theoretical IgA values, no signiﬁcant diffe
and patients with two different autoimmune diseases (AutoD1, AutoD2). However, when th
clear that patients with AutoD1 have an increase in IgA1 that is highly signiﬁcant. (For interp
version of this article.)galactosyltransferase (GTase) activity [70,71], which may be one
mechanism. Regardless of how they are created, the proin-
ﬂammatory nature of G0 glycans is becoming increasingly evident.
Investigators have demonstrated that IgGs bearing G0 glycans
at CH2-84.4 have increased afﬁnity for FcgRIII, an activating FcR.
They also serve as epitopes for lectin binding, including the
complement-activating mannose-binding lectins (MBLs) [72].
MBLs interact most efﬁciently with IgG-G0 clusters, an interaction
that has been linked to rapidly progressive RA [73]. In addition to
activation of the lectin pathway of complement, G0-decorated IgGs
can also activate both the classical and alternative complement
pathways making them especially problematic in the setting of
autoimmunity [74]. Another interesting ﬁnding is that elevations
in G0 glycans correlate with the onset of autoimmunity, as they
appear with increasing frequency after the age of 25 [75]. Lastly,
matching the epidemiology of autoimmunity, is the ﬁnding that
glycosylation proﬁles are altered in males and pregnant females.
The latter produce antibodies with increased galactose and sialic
acid moieties, which would ﬁt an anti-inﬂammatory proﬁle [69].
Similar to the effect observed with fucose, sialic acid containing
glycans at CH2-84.4 reduce IgG afﬁnity for FcgRIII, bestowing
it with anti-inﬂammatory properties [76]. Correlating with this
ﬁnding is the fact that sialylated IgGs are often decreased in the
setting of autoimmunity, promoting a pro-inﬂammatory state.
There is also a link between the therapeutic effect of intravenous
immunoglobulin (IVIG) and sialylation, which epitomizes the
importance of glycans containing sialic acid at CH2-84.4 [77]. IVIG
is a pooled preparation of immunoglobulin made from thousands
of donors and its anti-inﬂammatory properties have been known
for more than three decades [78,79]. IVIG's mechanism of action is
multifactorial but there is good evidence that it can function as a
SAMP. By binding to SAMP receptors on antigen presenting cells
IVIG can increase the expression of the inhibitory FcR, FcgRIIB, and
shorten the half-life of auto-reactive antibodies [80e82]. With
respect to sialylation, the anti-inﬂammatory properties of IVIG have
been mapped to the CH2-84.4 glycan within the Fc region of
IgG. Speciﬁcally, de-sialylated preparations of IVIG lose their ther-
apeutic activity and the anti-inﬂammatory effects of IVIG can be
recapitulated with administration of recombinant sialylated
IgG1 Fc [76]. From these ﬁndings, it is likely that in healthy in-
dividuals sialylated antibodies may function as endogenous
SAMPs, providing immune-modulatory effects by binding to SAMP
receptors. To date, SAMP receptors for sialylated IgG have not been
fully characterized but some evidence points to known immuno-
logically relevant lectins such as DC-SIGN, which are thought to be
required for the anti-inﬂammatory properties of IVIG [77].
The importance of CH2-84.4 glycans has also been extensively
demonstrated for commercial monoclonal antibodies. For example,
the efﬁcacy of rituximab, an anti-CD20 monoclonal used to treat
lymphoma, appears to be linked to its ability to bind FcgRIIIa
[83,84]. By producing anti-cancer monoclonal antibodies in a va-
riety of cell lines that differ in their glycosylation machinery it wastoimmunity. A) Without the need for additional puriﬁcation, serum or plasma from
. A C18 Nano-LC Chip is then employed to separate the peptides and glycopeptides form
en ionized using electron spray ionization and analyzed using a triple quadrupole time
requires prior knowledge of the collision-induced dissociation (CID) behavior of the
sitions to be developed for QqQ-MS detection. The process also requires a great deal of
ut once established MRM can rapidly identify peptide and glycopeptides from serum
f all four IgG subclasses (red arrow) is used for absolute quantitation of total IgG. IgG
r comparison to the common Fc region peptide to determine the relative abundance of
rence between total IgA or IgA subclass-speciﬁc titers is seen between healthy controls
e data is graphed as the relative abundance of the different IgA subclasses, it becomes
retation of the references to color in this ﬁgure legend, the reader is referred to the web
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superior anti-cancer properties [85]. Subsequently, it was demon-
strated that ADCC activity could be increased by producing
monoclonal antibodies in CHO cells engineered to over express
GnTIII, an enzyme that adds bisecting GlcNac residues [86,87]. An
alternative explanatory model for these results is that bisecting
glycans often lack fucose, the absence of which would increase IgG
afﬁnity for FcgRIIIa and subsequently promote ADCC [88e90].
Indeed the activity of rituximab is also increased when it is
produced in CHO cells that lack a(1e6) fucosyl transferase [88e90].
Although glycosylation of IgG has been extensively studied in
the setting of autoimmunity, less is known about the glycosylation
patterns of other immunoglobulins such as IgA and IgM in patients
with autoimmune diseases. This is due in part to our current lim-
itations in technology and the complexity of these glycosylated
proteins. IgA has two subclasses: IgA1 and IgA2, where IgA1 is
decorated with 5 O-glycans and 2 N-glycans and IgA2 is decorated
with 5 N-glycans. IgM, which typically exists as a homopentamer in
blood, also has 5 N-glycosylation sites on each of its heavy chains
(Fig. 1). It is likely that glycan alterations at these sites will have an
impact on how the immunoglobulins interact with other compo-
nents of the immune system and the relative abundances of these
glycans may also be indicative of speciﬁc autoimmune disease
states, which we are currently investigating.
6. Peptide and glycopeptide-speciﬁc technological
advancements in mass spectrometery
The majority of the early glycan proﬁling research used matrix-
assisted laser desorption/ionization (MALDI) mass spectrometry
(MS) [91e95] and generally focused on enzymatically released
glycans. Analyzing released N-glycans by MALDI MS yields
composition proﬁles that can be converted to putative structures
based on known biology, which is highly conserved. (N-Glycans
contain a common core composed of a chitobiose and a tri-
mannosyl moiety) (Fig. 2). Perhaps for this reason, the majority of
glycan proﬁling studies have characterized N-glycosylations.
However, MALDI MS proﬁling is limited because it does not provide
information on isomers and focusing on released glycans provides
no information about the originating sites of glycosylation. Such
information is important in order to develop a full understanding of
how glycans are related to the pathophysiology of autoimmunity.
Details on glycosylation sites are also important for biomarker
discovery research. We believe that accurately measuring the
relative abundance of individual site-speciﬁc glycan structures
within the immune system is the key to identifying glycan
biomarkers of autoimmunity.
One of themajor goals set forth by the National Research Council
of the National Academies is for the development of novel tech-
nology for the characterization of glycan structures [11]. To rapidly
identify autoimmune glycan signatures a technology that provides
absolute quantitation of all major serum proteins and their indi-
vidual glycoforms would be ideal. This would require, for example,
determination of the relative and absolute abundance of each IgG
subclass including their site-speciﬁc glycosylations. With this goal
in mind, our laboratory (CL) has used multiple reaction monitoring
(MRM) to reliably quantify the absolute and relative Ig glycoforms
directly from serum or plasma without the need for additional
enrichment procedures [96]. Although MRM has been used
extensively in metabolomics and proteomics [97e100], its high
sensitivity and linear response over a wide dynamic range make it
especially suited for glycan biomarker research and discovery. MRM
is performed on a triple quadrupole (QqQ) instrument, which is set
to detect a predetermined precursor ion in the ﬁrst quadrupole, a
fragmented in the collision quadrupole, and a predeterminedfragment ion in the third quadrupole. It is a non-scanning tech-
nique, wherein each transition is detected individually and the
detection of multiple transitions occurs concurrently in duty cycles.
Altering the cycle time (time spent monitoring all transitions in one
duty cycle) affects sampling efﬁciency and therefore data quality
while changes in dwell time (time spent acquiring a speciﬁc tran-
sition) affects the signal-to-noise ratio. To reduce the number of
concurrent transitions the number of monitored transitions per
glycopeptide can be decreased to a single transition. Single transi-
tion monitoring is possible because the typical fragment ions of a
glycan, the so-called “oxonium ions”, can easily identify the com-
pound as a glycopeptide and provide good quantitation.
The main advantage of MRM is that it allows the site-speciﬁc
glycosylation proﬁle to be normalized to the absolute protein
concentration. For IgG quantitation, a tryptic peptide common to the
Fc region of all four subclasses of IgG is used for total IgG quantiﬁ-
cation (Fig. 7). Simultaneously, subclass-speciﬁc peptides are used
to determine the absolute and relative quantities of all four IgG
subclasses (Fig. 7). Since IgMoccurs in a class all by itself, relative IgM
can be calculated using values for the high afﬁnity IgGs. By focusing
on relative abundance instead of total Ig concentration, signiﬁcant
disease-associated elevations of an Ig subclass become easy to
identify (Fig. 7). Importantly, this method does not require special
immunoglobulin enrichment procedures that may create bias for
speciﬁc structures and speciﬁc glycoforms. It is also rapid, allowing
for high throughput site-speciﬁc analyses, ideal for autoimmune
biomarker discovery. Combining MRM with ultrahigh pressure
liquid chromatography (UHPLC), utilizing a C18 nano-LC column,
provides excellent separation of glycopeptides and non-glycosylated
peptides at great speed (10e15min versus 50e90min inHPLC) prior
to mass spectrometry (Fig. 7). UHPLC also reduces charge competi-
tion during electrospray ionization, making the technique more
sensitive for glycoconjugate detection. Together this approach will
allow us to accurately determine an individual's serum glycome,
which will ultimately lead to the identiﬁcation of novel glycan
signatures of autoimmunity.
7. Summary and future directions
Although the role of glycans in the immune system is too broad
of a topic to successfully cover in one review, we have attempted to
highlight some of their important functions, especially with respect
to immune homeostasis. We predict that as we continue to develop
the appropriate analysis tools, it will become increasingly apparent
that a full understanding of one's immune glycomewill provide the
greatest insight into their overall immune health, including their
likelihood of developing autoimmunity or other immune abnor-
mality. As described above, MRM, is one innovative method capable
of quickly characterizing the relative abundance of different gly-
coconjugates within the serum of an individual. This technology
will be the key to identifying novel glycan biomarkers of autoim-
munity as well as other immunopathologies. The same technique
can also be applied to other human tissues and to experimental
systems, including animal models. Ultimately such research will
provide additional measures of disease phenotype, help predict
patients' responsiveness to treatment, and provide new insight into
the pathogenic immune response responsible for their disease.
We anticipate that in the near future glycan analysis will become
integral to the diagnosis and management of human disease.
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